GENEGUT will be strongly represented at the 15th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology (PBP World Meeting 2026), taking place in Prague, Czech Republic, from 23 to 26 March 2026. The event brings together leading experts from academia, industry and regulatory bodies to discuss advances in drug delivery, formulation and pharmaceutical technologies.
Showcasing GENEGUT research across oral and nucleic acid delivery
GENEGUT researchers will present their latest work across key sessions, highlighting the project’s integrated approach to developing innovative RNA-based therapies for ileal Crohn’s disease.
Oral presentations
- Miguel Ramôa will deliver an oral presentation entitled “Evaluation of Polymeric Nanoparticles for Intestinal Delivery of RNA for the Treatment of Ileal Crohn’s Disease”
Elisa Millet will present “Site specific oral delivery system to target the end of the ileum: from capsule design to biorelevant evaluation”
Poster presentations
Sophia Hoffmann will present “Functional RNA Nanoparticles for Oral Delivery: Stability Following Lyophilisation”
Ana Francisca Soares will present “Influence of PEGylation on Intestinal Transfection by Cyclodextrin-Based Nanoparticles”
Klara Martinović Mušić’s work will be presented by Silvia Melgar: “In vitro evaluation of Adrenomedullin as a Target for Oral RNA-based Therapy for Ileal Crohn’s Disease”
Aman Saifi’s poster will be presented by Silvia Melgar “Targeted delivery of RNA-based therapeutics to the gut to modulate the JAK-STAT pathway in Crohn’s Disease”
Advancing oral RNA therapeutics for Crohn’s disease
Together, these contributions reflect GENEGUT’s multidisciplinary strategy, spanning nanoparticle design, formulation stability, targeted delivery systems and therapeutic validation. The presentations demonstrate progress from early-stage formulation development to advanced delivery concepts aimed at clinical translation.
By contributing to key sessions at PBP 2026, GENEGUT continues to strengthen its scientific visibility and engagement within the international drug delivery and RNA therapeutics community.
We look forward to sharing further updates from Prague.
Follow us on LinkedIn for more project updates.